ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 152 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2016. The put-call ratio across all filers is 1.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $482,544 | -47.8% | 43,200 | 0.0% | 0.00% | -100.0% |
Q2 2023 | $924,480 | -46.3% | 43,200 | +1.4% | 0.00% | 0.0% |
Q1 2023 | $1,722,744 | -22.0% | 42,600 | -10.3% | 0.00% | -50.0% |
Q4 2022 | $2,209,700 | -8.8% | 47,500 | +1.7% | 0.00% | 0.0% |
Q3 2022 | $2,422,000 | +11.4% | 46,700 | +1.5% | 0.00% | +100.0% |
Q2 2022 | $2,174,000 | -29.5% | 46,000 | +6.2% | 0.00% | -50.0% |
Q1 2022 | $3,082,000 | +3.0% | 43,300 | +8.2% | 0.00% | 0.0% |
Q4 2021 | $2,991,000 | +31.6% | 40,000 | 0.0% | 0.00% | +100.0% |
Q3 2021 | $2,272,000 | +29.1% | 40,000 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $1,760,000 | -8.5% | 40,000 | +2.6% | 0.00% | 0.0% |
Q1 2021 | $1,923,000 | +18.6% | 39,000 | +1.3% | 0.00% | 0.0% |
Q4 2020 | $1,621,000 | -8.1% | 38,500 | 0.0% | 0.00% | 0.0% |
Q3 2020 | $1,763,000 | -7.1% | 38,500 | +1.9% | 0.00% | -50.0% |
Q2 2020 | $1,898,000 | +28.6% | 37,800 | +31.7% | 0.00% | 0.0% |
Q1 2020 | $1,476,000 | -15.6% | 28,700 | +1.4% | 0.00% | 0.0% |
Q4 2019 | $1,748,000 | +5.0% | 28,300 | +2.2% | 0.00% | 0.0% |
Q3 2019 | $1,664,000 | -27.2% | 27,700 | +2.2% | 0.00% | 0.0% |
Q2 2019 | $2,287,000 | -9.6% | 27,100 | +2.3% | 0.00% | -33.3% |
Q1 2019 | $2,531,000 | +39.1% | 26,500 | +3.1% | 0.00% | +50.0% |
Q4 2018 | $1,820,000 | -14.8% | 25,700 | +2.8% | 0.00% | 0.0% |
Q3 2018 | $2,137,000 | -26.3% | 25,000 | 0.0% | 0.00% | -33.3% |
Q2 2018 | $2,898,000 | +43.3% | 25,000 | 0.0% | 0.00% | +50.0% |
Q1 2018 | $2,023,000 | +46.7% | 25,000 | +6.4% | 0.00% | +100.0% |
Q4 2017 | $1,379,000 | +25.4% | 23,500 | 0.0% | 0.00% | 0.0% |
Q3 2017 | $1,100,000 | +30.0% | 23,500 | 0.0% | 0.00% | 0.0% |
Q2 2017 | $846,000 | +16.9% | 23,500 | 0.0% | 0.00% | 0.0% |
Q1 2017 | $724,000 | -3.1% | 23,500 | +5.4% | 0.00% | 0.0% |
Q4 2016 | $747,000 | +26.0% | 22,300 | 0.0% | 0.00% | 0.0% |
Q3 2016 | $593,000 | +20.5% | 22,300 | 0.0% | 0.00% | 0.0% |
Q2 2016 | $492,000 | +5.1% | 22,300 | +35.2% | 0.00% | 0.0% |
Q1 2016 | $468,000 | +5.9% | 16,500 | +23.1% | 0.00% | 0.0% |
Q4 2015 | $442,000 | -8.7% | 13,400 | 0.0% | 0.00% | 0.0% |
Q3 2015 | $484,000 | -8.0% | 13,400 | +14.5% | 0.00% | 0.0% |
Q2 2015 | $526,000 | +104.7% | 11,700 | +39.3% | 0.00% | 0.0% |
Q1 2015 | $257,000 | -39.8% | 8,400 | 0.0% | 0.00% | -50.0% |
Q4 2014 | $427,000 | +28.6% | 8,400 | 0.0% | 0.00% | +100.0% |
Q3 2014 | $332,000 | -8.3% | 8,400 | 0.0% | 0.00% | 0.0% |
Q2 2014 | $362,000 | +56.0% | 8,400 | +44.8% | 0.00% | 0.0% |
Q1 2014 | $232,000 | +98.3% | 5,800 | +34.9% | 0.00% | – |
Q4 2013 | $117,000 | – | 4,300 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 936,777 | $53,218,000 | 16.69% |
Fairmount Funds Management LLC | 316,952 | $18,006,000 | 6.55% |
ARMISTICE CAPITAL, LLC | 1,836,000 | $104,303,000 | 1.77% |
Soleus Capital Management, L.P. | 182,400 | $10,362,000 | 1.62% |
Portland Global Advisors LLC | 62,635 | $3,558,000 | 0.66% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 40,000 | $2,263,000 | 0.55% |
FARALLON CAPITAL MANAGEMENT LLC | 1,995,000 | $113,336,000 | 0.53% |
Yorktown Management & Research Co Inc | 10,400 | $591,000 | 0.44% |
Hennion & Walsh Asset Management, Inc. | 120,240 | $6,831,000 | 0.36% |
Virtus ETF Advisers LLC | 9,599 | $545,000 | 0.24% |